Case studies have reported that treatment of AD patients with the anti-TNF-α agents currently used in RA or Crohn’s disease, was beneficial and improved cognitive impairment17–19 while epidemiological studies showed that AD risk is reduced in RA patients receiving anti-TNF-α agents20. Here, TNF is linked to Crohn disease.